All Federal Grant Awards
Help

Project Grant R43MH133248

Award Date 9/1/22
Completion Date 8/31/24
Dollars Obligated $895K
Federal Agency
National Institute of Mental Health
Awardee
Neovaxsyn Inc. (EHMTBALCKFE8)
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Ames, IA 50014, USA
Similar Awards
Project Grant R01AI186793
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This $3,454,926 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to define the optimal pathway from antibody precursors to broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein apex epitope. The research aims to refine the understanding of common apex bNAb precursors found in uninfected individuals and identify SOSIP-TM antigens that can...
Project Grant R01AI183970
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This Project Grant award of $1,547,482 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to define and refine strategies for using broadly neutralizing antibodies (bnAbs) to restrict HIV replication in vivo. The project will rigorously test two distinct approaches to enhance the antiviral activity of bnAbs: 1) using Fc engineering to improve bnAb antiviral activity across diverse envelope epitopes,...
Project Grant R21AI181677
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
The federal Project Grant award R21AI181677, totaling $228,825.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to develop an improved HIV vaccine by synergizing neutralizing and non-neutralizing antibody targets at the HIV/SIV viral spike apex. The research aims to 1) design and validate a V2B-focused immunogen, and 2) test the combination of...
Project Grant R01AI186784
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $807,257 Project Grant to Old Dominion University to develop and test a microneedle patch technology for delivering a cocktail of broadly neutralizing antibodies (BnAbs) to prevent HIV-1 transmission in breastfeeding infants. The project aims to design and fabricate a user-friendly transdermal microneedle patch that can co-deliver three...
Project Grant R01AI187016
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This $737,761.00 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to enhance HIV prevention with a vaccine approach that promotes durable immunity. The key products and services to be delivered include: Detailed immune analyses to uncover mechanisms of effective T follicular helper (Tfh) cell-mediated humoral immunity against HIV, using both DNA and mRNA vaccine platforms in rhesus macaques. The...
Project Grant P01AI181044
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an effective HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The $7,105,240 award supports a 5-year research program with the University of California, Davis as the prime recipient. The program includes three main projects: Project 1 will examine...
Project Grant F30AI186662
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $107,948 to the University of Southern California (USC) to develop an approach to engineer B cells to secrete broadly neutralizing antibodies (bNAbs) that can control HIV in people living with HIV (PLWH). The key objectives of this 4.5-year project are to: 1) design synthetic protein signaling molecules that can...
Project Grant R43AI191927
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $300,000 to support pre-clinical IND-enabling studies for a long-acting recombinant protein therapeutic called ECD4-Ig. ECD4-Ig is an antibody-like therapeutic for HIV that recognizes all HIV isolates and cannot be escaped by the virus. The funding will enable the awardee, Emmune Inc., to conduct critical in...
Project Grant F30AI179430
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,256 to fund research aimed at eliciting broadly neutralizing antibodies (bNAbs) against HIV-1 through a two-pronged approach. The first aim involves rigorously dissecting the evolution of a bNAb precursor-like lineage using an immunoglobulin knockin mouse model. The second aim will study antibody-virus coevolution...
Project Grant R01AI179584
Logo for National Institute of Allergy and Infectious Diseases (HHS - NIH)
This Project Grant award, with a total funding amount of $667,848, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research to investigate the molecular and phenotypic features of pre-existing HIV gp120-specific B cells, and how these B cell populations respond to HIV vaccination in high-risk individuals, including those using pre-exposure prophylaxis (PrEP). The...

INDUCTION OF BNABS AGAINST HIV-1 GP41. - PROJECT SUMMARY/ABSTRACT DESPITE THE AVAILABILITY OF EFFECTIVE ANTI-RETROVIRAL DRUGS, THERE ARE STILL ABOUT 38 MILLION PEOPLE LIVING WITH HIV-1 INFECTION AND ABOUT 1.5 MILLION PEOPLE BECAME NEWLY INFECTED JUST IN 2020. A VACCINE IS CRITICALLY NEEDED TO STOP THE AIDS PANDEMIC. INDUCTION OF BROADLY NEUTRALIZING ANTIBODIES (BNABS) AGAINST HIV-1 IS THE UTMOST CRITICAL GOAL TOWARDS THE DEVELOPMENT OF A PROTECTIVE AIDS VACCINE. IN THIS R43 PHASE I SBIR PROPOSAL, WE WILL EVALUATE A NOVEL "ANTIBODY- STABILIZED, EPITOPE PRESENTATION" (ASEP) VACCINE STRATEGY TO ELICIT 10E8-LIKE BNABS AGAINST HIV-1. 10E8, A BNAB ISOLATED FROM AN HIV-1-INFECTED PATIENT THAT TARGETS THE MEMBRANE PROXIMAL EXTERNAL REGION (MPER) OF HIV-1 GP41, HAS BEEN SHOWN TO NEUTRALIZE ~98% OF ALL HIV-1 ISOLATES TESTED. DEVELOPING IMMUNOGENS AND/OR ESTABLISHING VACCINE STRATEGIES THAT CAN INDUCE 10E8-LIKE BNABS WOULD BE A MAJOR MILESTONE TOWARDS AIDS VACCINE DEVELOPMENT. THUS, OUR PROPOSAL IS HIGHLY SIGNIFICANT AND, IF SUCCESSFUL, THIS PROJECT WILL HAVE GREAT IMPACT IN THE AIDS VACCINE FIELD AND IMMUNOGENS WE GENERATE WILL BE COMMERCIALLY VALUABLE. THE MAJOR INNOVATION AND THE FOCUS OF THIS PROPOSAL IS OUR ASEP VACCINE STRATEGY, IN WHICH PRECISELY DEFINED IMMUNE COMPLEXES ARE USED AS IMMUNOGENS. THIS PROPOSAL IS FOUNDED ON THREE SCIENTIFIC PREMISES. (1) A VACCINE THAT CAN INDUCE HIGH TITERS OF 10E8-LIKE BNABS WILL BE PROTECTIVE AGAINST HIV-1 INFECTIONS. (2) ALTHOUGH SHORT PEPTIDES ARE GOOD FOR FOCUSING ANTIBODY RESPONSES, THEY ARE NOT IDEAL B-CELL IMMUNOGENS BECAUSE THEY ARE HIGHLY FLEXIBLE AND CAN EXIST IN MANY DIFFERENT CONFORMATIONS. (3) THE CONFORMATION OF A PEPTIDE CAN BE FIXED INTO A RIGID STRUCTURE WHEN IT IS BOUND TO AN ANTIBODY. THE PRIMARY OBJECTIVE OF THIS PHASE I R43 FEASIBILITY STUDY IS TO DEMONSTRATE MPER/ANTIBODY IMMUNE COMPLEXES CAN BE USED TO ELICIT 10E8-LIKE BNABS AGAINST HIV-1. SUCCESSFUL COMPLETION OF THIS STUDY WOULD OVERCOME A CRITICAL ROADBLOCK TOWARDS DEVELOPMENT OF A PROTECTIVE AIDS VACCINE.

Posted 9/1/22, 12:00 AM